Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04322682 · ClinicalTrials.gov registry record · Phase 3
Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)
A Phase 3 study, sponsored by Montreal Heart Institute.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4,506
- Enrollment target
NCT04322682 is a Phase 3 study that was terminated before completion, run by Montreal Heart Institute. The registered enrollment target is 4,506 participants.
The verdict
NCT04322682, a Phase 3 study, was terminated before completion, sponsored by Montreal Heart Institute.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4,506 participants
- Enrollment target
Study Summary
This is a phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and have at least one high-risk criterion. Approximately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo tablets for 30 days.
Interventions
- DRUG Colchicine
- DRUG Placebo oral tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,506 participants |
| Start Date | 2020-03-23 |
| Est. Completion | 2021-01-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04322682
The ClinicalTrials.gov registry entry for NCT04322682 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4,506 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montreal Heart Institute, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Colchicine is the first listed.
NCT04322682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04322682 about?
NCT04322682 is a clinical study titled "Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)". This is a phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and have at least one high-risk criterion. Approximately 6000 subjects meeting all inclusion and no exclusion criter...
What is the current status of trial NCT04322682?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4,506 participants. The study started on 2020-03-23. Estimated completion is 2021-01-21.
What interventions are being tested in trial NCT04322682?
The interventions under investigation include: Colchicine (DRUG), Placebo oral tablet (DRUG).
Who is sponsoring clinical trial NCT04322682?
This trial is sponsored by Montreal Heart Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.